SCHEMBL7529026

SCHEMBL7529026

CC(=O)c1cccc(N[C]=O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.59
MEN1 O00255 4/20 0.59
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
ALDH1A1 P00352 6/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
TDP1 Q9NUW8 1/20 0.57
MAPK1 P28482 3/20 0.53
HTT P42858 2/20 0.53
CREBBP Q92793 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
POLB P06746 1/20 0.51
CYP1A2 P05177 1/20 0.51
MAPT P10636 2/20 0.51
USP2 O75604 1/20 0.51
TP53 P04637 1/20 0.51
PKM P14618 1/20 0.51
TSHR P16473 1/20 0.51
MCL1 Q07820 1/20 0.51
NOX1 Q9Y5S8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11335359 0.84 KMT2A (0.57) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL2444355 0.83 AKR1C3 (0.53) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL2445250 0.82 RAB9A (0.59) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL27789671 0.81 MEN1 (0.54) KMT2AMEN1
SCHEMBL474709 0.79 KMT2A (0.70) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL5340030 0.79 MEN1 (0.89) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL30478066 0.79 ALDH1A1 (0.66) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL14641620 0.79 KMT2A (0.65) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL7768635 0.79 ALDH1A1 (0.66) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL630874 0.77 MEN1 (0.42) KMT2AMEN1RAB9AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 EP claimed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US claimed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO claimed
US-20130165446-A1 BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE HORIKOSHI, HIROYOSHI (CA) 2013-06-27 US disclosed
EP-2581373-A1 BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE Fujita, Takashi (JP) 2013-04-17 EP disclosed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165446-A1 BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE PPARG, PPARA, PPARD KMT2A 1996/4885MEN1 4822/4885NPC1 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.